World Library  
Flag as Inappropriate
Email this Article


Systematic (IUPAC) name
Clinical data
Trade names Klonopin, Rivotril, Clonotril
Licence data US FDA:
  • AU: C
  • US: D (Evidence of risk)
Legal status
Routes of
Oral, I.M., I.V, sublingual
Pharmacokinetic data
Bioavailability 90%
Protein binding ~85%
Metabolism Liver CYP3A4
Onset of action Within an hour[2]
Biological half-life 18–50 hours
Duration of action 6 to 12 hr[2]
Excretion Kidney
CAS Registry Number  Y
ATC code N03
PubChem CID:
DrugBank  Y
ChemSpider  Y
Chemical data
Formula C15H10ClN3O3
Molecular mass 315.715

Clonazepam, sold under the brand name Klonopin among others, is a medication used to prevent and treat seizures, panic disorder, and for the movement disorder known as akathisia.[3] It is a tranquilizer known as a benzodiazepine. It is taken by mouth.[3] It begins having an effect within an hour and lasts between six and twelve hours.[2] Common side effects include sleepiness, poor coordination, and agitation. It may increase risk of suicide. Long term use may result in tolerance, dependence, and withdrawal symptoms if stopped.[3] Dependence occurs in one third of people who take clonazepam for longer than four weeks.[4] If used during pregnancy it may result in harm to the baby.[3] It binds to GABAA receptors and increases the effect of the neurotransmitter GABA.[4] Clonazepam was initially patented in 1964 and went on sale in the United States in 1975.[5] It is available as a generic medication.[3] Wholesale it costs between 0.01 and 0.07 USD per pill.[6] In the United States the pills are about 0.40 USD each.[3] In many areas of the world it is commonly used as a recreational drug.[7][8]


  • Medical uses 1
    • Seizures 1.1
    • Anxiety disorders 1.2
    • Muscle disorders 1.3
    • Other 1.4
  • Adverse effects 2
    • Common 2.1
    • Less common 2.2
    • Occasional 2.3
    • Rare 2.4
    • Drowsiness 2.5
    • Withdrawal-related 2.6
    • Tolerance and withdrawal 2.7
    • Overdose 2.8
    • Detection in biological fluids 2.9
    • Special precautions 2.10
  • Interactions 3
  • Pregnancy 4
  • Mechanism of action 5
  • Pharmacokinetics 6
  • Society and culture 7
    • Recreational use 7.1
    • Formulations 7.2
    • Brand names 7.3
  • References 8
  • External links 9

Medical uses

Clonazepam may be prescribed for epilepsy[9][10] or anxiety disorders.


Clonazepam, like other benzodiazepines, while being a first-line treatment for acute seizures, is not suitable for the long-term treatment of seizures due to the development of tolerance to the anti-convulsant effects.

Clonazepam has been found effective in treating epilepsy in children, and the inhibition of seizure activity seemed to be achieved at low plasma levels of clonazepam.[11] As a result, clonazepam is sometimes used for certain rare childhood epilepsies; however, it has been found to be ineffective in the control of infantile spasms.[12] Clonazepam is mainly prescribed for the acute management of epilepsies. Clonazepam has been found to be effective in the acute control of non-convulsive status epilepticus; however, the benefits tended to be transient in many of the people, and the addition of phenytoin for lasting control was required in these patients.[13]

It is also approved for treatment of typical and atypical absences, infantile myoclonic, myoclonic and akinetic seizures[14] A subgroup of people with treatment resistant epilepsy may benefit from long-term use of clonazepam; the benzodiazepine clorazepate may be an alternative due to its slow onset of tolerance.[4]

Anxiety disorders

Clonazepam has also been found effective in treating:

The effectiveness of clonazepam in the short-term treatment of panic disorder has been demonstrated in controlled clinical trials. Some long-term trials have suggested a benefit of clonazepam for up to three years without the development of tolerance but these trials were not placebo-controlled. Clonazepam is also effective in the management of acute mania.[17]

Muscle disorders

Restless legs syndrome can be treated using clonazepam as a third-line treatment option as the use of clonazepam is still investigational.[18][19] Bruxism also responds to clonazepam in the short-term.[20] Rapid eye movement behavior disorder responds well to low doses of clonazepam.[21]


Adverse effects


Less common

  • Confusion[4]
  • Irritability and aggression[32]
  • Psychomotor agitation[33]
  • Lack of motivation[34]
  • Loss of libido
  • Impaired motor function
    • Impaired coordination
    • Impaired balance
    • Dizziness
  • Cognitive impairments[35]
  • Some users report hangover-like symptoms of drowsiness, headaches, sluggishness, and irritability upon waking up if the medication was taken before sleep. This is likely the result of the medication's long half-life, which continues to affect the user after waking up.

[39][40] While benzodiazepines induce sleep, they tend to reduce the quality of sleep by suppressing or disrupting REM sleep.[41] After regular use, rebound insomnia may occur when discontinuing clonazepam.[42]

  • Benzodiazepines may cause or worsen depression.[4]


  • Dysphoria[43]
  • Thrombocytopenia[44]
  • Induction of seizures[45][46] or increased frequency of seizures[47]
  • Personality changes[48]
  • Behavioural disturbances[49]
  • Ataxia[4]


  • Psychosis[50]
  • Incontinence[51][52][53]
  • Liver damage[54]
  • Paradoxical behavioural disinhibition[4][55] (most frequently in children, the elderly, and in persons with developmental disabilities)
    • Rage
    • Excitement
    • Impulsivity

The long-term effects of clonazepam can include depression,[4] disinhibition, and sexual dysfunction.[56]


Clonazepam, like other benzodiazepines, impair a persons ability to drive or operate machinery. The central nervous system-depressing effects of the drug can be intensified by alcohol consumption, and therefore alcohol should be avoided while taking this medication. Benzodiazepines have been shown to cause both psychological and physical dependence. Patients physically dependent on clonazepam should be slowly titrated off under the supervision of a qualified healthcare professional to reduce the intensity of withdrawal or rebound symptoms.


  • Anxiety, irritability, insomnia, tremors
  • Potential to exacerbate existing panic disorder upon discontinuation
  • Seizures[57] similar to delirium tremens (with long-term use of excessive doses)

Benzodiazepines such as clonazepam can be very effective in controlling status epilepticus, but, when used for longer periods of time, some potentially serious side-effects may develop, such as interference with cognitive functions and behavior.[58] Many individuals treated on a long-term basis develop a form of dependence known as "low-dose dependence", as was shown in one double-blind, placebo-controlled study of 34 therapeutic low-dose benzodiazepine users. Physiological dependence was demonstrated by flumazenil-precipitated withdrawal.[59] Use of alcohol or other CNS depressants while taking clonazepam greatly intensifies the effects (and side-effects) of the drug.

Tolerance and withdrawal

Like all benzodiazepines, clonazepam is a GABA positive allosteric modulator.[60][61] One-third of individuals treated with benzodiazepines for longer than four weeks develop a dependence on the drug and experience a withdrawal syndrome upon dose reduction. High dosage and long-term use increases the risk and severity of dependence and withdrawal symptoms. Withdrawal seizures and psychosis can occur in severe cases of withdrawal, and anxiety and insomnia can occur in less severe cases of withdrawal. Gradual reduction in dosage reduces the severity of the benzodiazepine withdrawal syndrome. Due to the risks of tolerance and withdrawal seizures, clonazepam is generally not recommended for the long-term management of epilepsies. Increasing the dose can overcome the effects of tolerance, but tolerance to the higher dose may occur and adverse effects may intensify. The mechanism of tolerance includes receptor desensitisation, down regulation, receptor decoupling, and alterations in subunit composition and in gene transcription coding.[4]

Tolerance to the anticonvulsant effects of clonazepam occurs in both animals and humans. In humans, tolerance to the anticonvulsant effects of clonazepam occurs frequently.[62][63] Chronic use of benzodiazepines can lead to the development of tolerance with a decrease of benzodiazepine binding sites. The degree of tolerance is more pronounced with clonazepam than with chlordiazepoxide.[64] In general, short-term therapy is more effective than long-term therapy with clonazepam for the treatment of epilepsy.[65] Many studies have found that tolerance develops to the anticonvulsant properties of clonazepam with chronic use, which limits its long-term effectiveness as an anticonvulsant.[66]

Abrupt or over-rapid withdrawal from clonazepam may result in the development of the benzodiazepine withdrawal syndrome, causing psychosis characterised by dysphoric manifestations, irritability, aggressiveness, anxiety, and hallucinations.[67][68][69] Sudden withdrawal may also induce the potentially life-threatening condition, status epilepticus. Anti-epileptic drugs, benzodiazepines such as clonazepam in particular, should be reduced in dose slowly and gradually when discontinuing the drug to mitigate withdrawal effects.[48] Carbamazepine has been tested in the treatment of clonazepam withdrawal but was found to be ineffective in preventing clonazepam withdrawal-induced status epilepticus from occurring.[70]


Excess doses may result:

Coma can be cyclic, with the individual alternating from a comatose state to a hyper-alert state of consciousness, which occurred in a 4-year-old boy who suffered an overdose of clonazepam.[71] The combination of clonazepam and certain barbiturates, e.g. amobarbital, at prescribed doses has resulted in a synergistic potentiation of the effects of each drug, leading to serious respiratory depression.[72]

Overdose symptoms may include extreme drowsiness, confusion, muscle weakness, and fainting.[73]

Although an overdose of clonazepam is a serious medical concern, there have been no known instances of death from such an overdose. The LD50 for both mice and rats is greater than 2,000 mg per kilogram of body weight.[74]

Detection in biological fluids

Clonazepam and 7-aminoclonazepam may be quantified in plasma, serum or whole blood in order to monitor compliance in those receiving the drug therapeutically. Results from such tests can be used to confirm the diagnosis in potential poisoning victims or to assist in the forensic investigation in a case of fatal overdosage. Both the parent drug and 7-aminoclonazepam are unstable in biofluids, and therefore specimens should be preserved with sodium fluoride, stored at the lowest possible temperature and analyzed quickly to minimize losses.[75]

Special precautions

The elderly metabolise benzodiazepines more slowly than younger individuals and are also more sensitive to the effects of benzodiazepines, even at similar blood plasma levels. Doses for the elderly are recommended to be about half of that given to younger adults and are to be administered for no longer than two weeks. Long-acting benzodiazepines such as clonazepam are not generally recommended for the elderly due the risk of drug accumulation.[4]

The elderly are especially susceptible to increased risk of harm from motor impairments and drug accumulation side effects. Benzodiazepines also require special precaution if used by individuals that may be pregnant, alcohol- or drug-dependent, or may have comorbid psychiatric disorders.[76] Clonazepam is generally not recommended for use in elderly people for insomnia due to its high potency relative to other benzodiazepines.[77]

Clonazepam is not recommended for use in those under 18. Use in very young children may be especially hazardous. Of anticonvulsant drugs, behavioural disturbances occur most frequently with clonazepam and phenobarbital.[76][78]

Doses higher than 0.5–1 mg per day are associated with significant sedation.[79]

Clonazepam may aggravate hepatic porphyria.[80][81]

Clonazepam is not recommended for patients with chronic schizophrenia. A 1982 double-blinded, placebo-controlled study found clonazepam increases violent behavior in individuals with chronic schizophrenia.[82]


Clonazepam decreases the levels of carbamazepine,[83][84] and, likewise, clonazepam's level is reduced by carbamazepine. Azole antifungals, such as ketoconazole, may inhibit the metabolism of clonazepam.[4] Clonazepam may affect levels of phenytoin (diphenylhydantoin).[83][85][86][87] In turn, Phenytoin may lower clonazepam plasma levels by increasing the speed of clonazepam clearance by approximately 50% and decreasing its half-life by 31%.[88] Clonazepam increases the levels of primidone[86] and phenobarbital.[89]

Combined use of clonazepam with certain antidepressants, antiepileptics, such as phenobarbital, phenytoin and carbamazepine, sedative antihistamines, opiates, antipsychotics, nonbenzodiazepine hypnotics like zolpidem and alcohol may result in enhanced sedative effects.[4]


There is some medical evidence of various malformations, e.g., cardiac or facial deformations, when used in early pregnancy; however, the data is not conclusive. The data are also inconclusive on whether benzodiazepines such as clonazepam cause developmental deficits or decreases in IQ in the developing fetus when taken by the mother during pregnancy. Clonazepam, when used late in pregnancy, may result in the development of a severe benzodiazepine withdrawal syndrome in the neonate. Withdrawal symptoms from benzodiazepines in the neonate may include hypotonia, apnoeic spells, cyanosis and impaired metabolic responses to cold stress.[90]

The safety profile of clonazepam during pregnancy is less clear than that of other benzodiazepines, and if benzodiazepines are indicated during pregnancy, chlordiazepoxide and diazepam may be a safer choice. The use of clonazepam during pregnancy should only occur if the clinical benefits are believed to outweigh the clinical risks to the fetus. Caution is also required if clonazepam is used during breast feeding. Possible adverse effects of use of benzodiazepines such as clonazepam during pregnancy include: miscarriage, malformation, intrauterine growth retardation, functional deficits, floppy infant syndrome, carcinogenesis and mutagenesis. Neonatal withdrawal syndrome associated with benzodiazepines include hypertonia, hyperreflexia, restlessness, irritability, abnormal sleep patterns, inconsolable crying, tremors or jerking of the extremities, bradycardia, cyanosis, suckling difficulties, apnea, risk of aspiration of feeds, diarrhea and vomiting, and growth retardation. This syndrome can develop between 3 days to 3 weeks after birth and can have a duration of up to several months. The pathway by which clonazepam is metabolised is usually impaired in newborns. If clonazepam is used during pregnancy or breast feeding, it is recommended that serum levels of clonazepam are monitored and that signs of central nervous system depression and apnea are also checked for. In many cases, non-pharmacological treatments, such as relaxation therapy, psychotherapy and avoidance of caffeine, can be an effective and safer alternative to the use of benzodiazepines for anxiety in pregnant women.[91]

Mechanism of action

Clonazepam acts by binding to the benzodiazepine site of the GABA receptors, which enhances the electric effect of GABA binding on neurons, resulting in an increased influx of chloride ions into the neurons. This further results in an inhibition of synaptic transmission across the central nervous system.[92][93]

Benzodiazepines do not have any effect on the levels of GABA in the brain.[94] Clonazepam has no effect on GABA levels and has no effect on gamma-aminobutyric acid transaminase. Clonazepam does, however, affect glutamate decarboxylase activity. It differs from other anticonvulsant drugs it was compared to in a study.[95]

Clonazepam's primary mechanism of action is the modulation of GABA function in the brain, by the benzodiazepine receptor, located on GABAA receptors, which, in turn, leads to enhanced GABAergic inhibition of neuronal firing. Benzodiazepines do not replace GABA, but instead enhance the effect of GABA at the GABAA receptor by increasing the opening frequency of chloride ion channels, which leads to an increase in GABA's inhibitory effects and resultant central nervous system depression.[4] In addition, clonazepam decreases the utilization of 5-HT (serotonin) by neurons[96][97] and has been shown to bind tightly to central-type benzodiazepine receptors.[98] Because clonazepam is effective in low milligram doses (0.5 mg clonazepam = 10 mg diazepam),[99] it is said to be among the class of "highly potent" benzodiazepines.[100] The anticonvulsant properties of benzodiazepines are due to the enhancement of synaptic GABA responses, and the inhibition of sustained, high-frequency repetitive firing.[101]

Benzodiazepines, including clonazepam, bind to mouse glial cell membranes with high affinity.[102][103] Clonazepam decreases release of acetylcholine in the feline brain[104] and decreases prolactin release in rats.[105] Benzodiazepines inhibit cold-induced thyroid stimulating hormone (also known as TSH or thyrotropin) release.[106] Benzodiazepines acted via micromolar benzodiazepine binding sites as Ca2+ channel blockers and significantly inhibit depolarization-sensitive calcium uptake in experimentation on rat brain cell components. This has been conjectured as a mechanism for high-dose effects on seizures in the study.[107]

Clonazepam is a chlorinated derivative of nitrazepam[108] and therefore a chloro-nitrobenzodiazepine.[109]


Clonazepam is lipid-soluble, rapidly crosses the blood–brain barrier, and penetrates the placenta. It is extensively metabolised into pharmacologically inactive metabolites. Clonazepam is metabolized extensively via nitroreduction by cytochrome P450 enzymes, particularly CYP2C19 and to a lesser extent CYP3A4. Erythromycin, clarithromycin, ritonavir, itraconazole, ketoconazole, nefazodone, and grapefruit juice are inhibitors of CYP3A4 and can affect the metabolism of benzodiazepines.[110] It has an elimination half-life of 19–60 hours.[4] Peak blood concentrations of 6.5–13.5 ng/mL were usually reached within 1–2 hours following a single 2 mg oral dose of micronized clonazepam in healthy adults. In some individuals, however, peak blood concentrations were reached at 4–8 hours.[111]

Clonazepam passes rapidly into the central nervous system, with levels in the brain corresponding with levels of unbound clonazepam in the blood serum.[112] Clonazepam plasma levels are very unreliable amongst patients. Plasma levels of clonazepam can vary as much as tenfold between different patients.[113]

Clonazepam is largely bound to plasma proteins.[114] Clonazepam passes through the blood–brain barrier easily, with blood and brain levels corresponding equally with each other.[115] The metabolites of clonazepam include 7-aminoclonazepam, 7-acetaminoclonazepam and 3-hydroxy clonazepam.[116][117]

Society and culture

Recreational use

A 2006 US government study of emergency department visits found that sedative-hypnotics were the most frequently implicated pharmaceutical drug in ED visits, with benzodiazepines accounting for the majority of these. Clonazepam was the second most frequently implicated benzodiazepine in ED visits, however it should be noted that alcohol alone was responsible for over twice as many ED visits than clonazepam in the same study. The study examined the number of times non-medical use of certain drugs were implicated in ED visit. The criteria for non-medical use in this study were purposefully broad, and include, for example, drug abuse, accidental or intentional overdose, or adverse reactions resulting from legitimate use of the medication.[118]


Klonopin 0.5 mg.
Klonopin 1 mg.

Clonazepam was approved in the United States as a generic drug in 1997 and is now manufactured and marketed by several companies.

Clonazepam is available as tablets (0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg) and orally disintegrating tablets (wafers) (0.25 mg, 0.5 mg), an oral solution (drops), and as a solution for injection or intravenous infusion.

Brand names

It is marketed under the trade name Rivotril by Roche in Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Colombia, Costa Rica, Croatia, the Czech Republic, Denmark, Germany, Hungary, Ireland, Italy, Mexico, the Netherlands, Norway, Portugal, Peru, Romania, South Africa, Spain, Turkey, and the United States; Linotril and Clonotril in India, South Korea, and other parts of Europe; and under the trade name Klonopin by Roche in the United States. Other names, such as Ravotril, Rivatril, Rivotril, Iktorivil, Clonex, Paxam, Petril, Naze and Kriadex, are known throughout the world.


  1. ^ Saunders Nursing Drug Handbook 2014
  2. ^ a b c Cooper, edited by Grant (2007). Therapeutic uses of botulinum toxin. Totowa, N.J.: Humana Press. p. 214.  
  3. ^ a b c d e f "Clonazepam". The American Society of Health-System Pharmacists. Retrieved Aug 15, 2015. 
  4. ^ a b c d e f g h i j k l m n Riss, J.; Cloyd, J.; Gates, J.; Collins, S. (Aug 2008). "Benzodiazepines in epilepsy: pharmacology and pharmacokinetics." (PDF). Acta Neurol Scand 118 (2): 69–86.  
  5. ^ Shorter, Edward (2005). "B". A Historical Dictionary of Psychiatry. Oxford University Press.  
  6. ^ "Clonazepam". International Drug Price Indicator Guide. Retrieved 15 August 2015. 
  7. ^ Martino, edited by Davide; Cavanna, Andrea E. (2013). Advances in the neurochemistry and neuropharmacology of Tourette Syndrome. Burlington: Elsevier Science. p. 357.  
  8. ^ Fisher, Gary L. (2009). Encyclopedia of substance abuse prevention, treatment, & recovery. Los Angeles: SAGE. p. 100.  
  9. ^ Rossetti AO; Reichhart MD; Schaller MD; Despland PA; Bogousslavsky J (July 2004). "Propofol treatment of refractory status epilepticus: a study of 31 episodes". Epilepsia 45 (7): 757–63.  
  10. ^ Ståhl Y, Persson A, Petters I, Rane A, Theorell K, Walson P; Persson; Petters; Rane; Theorell; Walson (April 1983). "Kinetics of clonazepam in relation to electroencephalographic and clinical effects". Epilepsia 24 (2): 225–31.  
  11. ^ Dahlin MG, Amark PE, Nergårdh AR; Amark; Nergårdh (January 2003). "Reduction of seizures with low-dose clonazepam in children with epilepsy". Pediatr. Neurol. 28 (1): 48–52.  
  12. ^ Hrachovy RA, Frost JD Jr, Kellaway P, Zion TE; Frost Jr; Kellaway; Zion (October 1983). "Double-blind study of ACTH vs prednisone therapy in infantile spasms". J Pediatr 103 (4): 641–5.  
  13. ^ Tomson T; Svanborg E, Wedlund JE (May–Jun 1986). "Nonconvulsive status epilepticus: high incidence of complex partial status". Epilepsia 27 (3): 276–85.  
  14. ^ Browne TR (May 1976). "Clonazepam. A review of a new anticonvulsant drug". Arch. Neurol. 33 (5): 326–32.  
  15. ^ Davidson, Jonathan; et al. (1993). "Treatment of Social Phobia With Clonazepam and Placebo". Journal of Clinical Psychopharmacology 13: 423–428.  
  16. ^ Cloos, Jean-Marc (2005). "The Treatment of Panic Disorder". Curr Opin Psychiatry 18 (1): 45–50.  
  17. ^ Nardi, AE.; Perna, G. (May 2006). "Clonazepam in the treatment of psychiatric disorders: an update". Int Clin Psychopharmacol 21 (3): 131–42.  
  18. ^ "[Restless legs syndrome: diagnosis and treatment. Opinion of Brazilian experts]". Arq Neuropsiquiatr 65 (3A): 721–7. Sep 2007.  
  19. ^ Trenkwalder, C.; Hening, WA.; Montagna, P.; Oertel, WH.; Allen, RP.; Walters, AS.; Costa, J.; Stiasny-Kolster, K.; Sampaio, C. (Dec 2008). "Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice" (PDF). Mov Disord 23 (16): 2267–302.  
  20. ^ Huynh, NT.; Rompré, PH.; Montplaisir, JY.; Manzini, C.; Okura, K.; Lavigne, GJ. (2006). "Comparison of various treatments for sleep sex bruxism using determinants of number needed to treat and effect size". Int J Prosthodont 19 (5): 435–41.  
  21. ^ Ferini-Strambi, L.; Zucconi, M. (Sep 2000). "REM sleep behavior disorder". Clin Neurophysiol. 111 Suppl 2: S136–40.  
  22. ^
  23. ^ "Successful treatment with clonazepam for neuroleptic-induced akathisia". 
  24. ^ Lipton, S.A.; Rosenberg, P.A.; Rosenberg, Paul A. (1994). "Excitatory amino acids as a final common pathway for neurological disorders".  
  25. ^ Bird, RD; Makela, EH (January 1994). "Alcohol withdrawal: what is the benzodiazepine of choice?". The Annals of pharmacotherapy 28 (1): 67–71.  
  26. ^ Curtin F, Schulz P; Schulz (2004). "Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis". J Affect Disord 78 (3): 201–8.  
  27. ^ Gillies D, Beck A, McCloud A, Rathbone J, Gillies D; Beck; McCloud; Rathbone; Gillies (2005). Gillies, Donna, ed. "Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis". Cochrane Database Syst Rev (4): CD003079.  
  28. ^ Zhou, L.; Chillag, KL.; Nigro, MA. (Oct 2002). "Hyperekplexia: a treatable neurogenetic disease". Brain Dev 24 (7): 669–74.  
  29. ^ Schenck, CH.; Arnulf, I.; Mahowald, MW. (Jun 2007). "Sleep and Sex: What Can Go Wrong? A Review of the Literature on Sleep Related Disorders and Abnormal Sexual Behaviors and Experiences". Sleep 30 (6): 683–702.  
  30. ^ Mulleners, WM; Chronicle, EP (June 2008). "Anticonvulsants in migraine prophylaxis: a Cochrane review.". Cephalalgia : an international journal of headache 28 (6): 585–97.  
  31. ^ Stacy, M. (2002). "Sleep disorders in Parkinson's disease: epidemiology and management". Drugs Aging 19 (10): 733–9.  
  32. ^ Lander CM; Donnan GA; Bladin PF; Vajda FJ (1979). "Some aspects of the clinical use of clonazepam in refractory epilepsy". Clin Exp Neurol 16: 325–32.  
  33. ^ Sorel L; Mechler L; Harmant J (1981). "Comparative trial of intravenous lorazepam and clonazepam im status epilepticus". Clin Ther 4 (4): 326–36.  
  34. ^ Wollman M; Lavie P; Peled R (1985). "A hypernychthemeral sleep-wake syndrome: a treatment attempt". Chronobiol Int 2 (4): 277–80.  
  35. ^ Aronson, Jeffrey Kenneth (20 Nov 2008). Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects). Elsevier Science. p. 403.  
  36. ^ "Clonazepam Side Effects". 2010. 
  37. ^ The interface of neurology internal medicine. Philadelphia: Wolters Kluwer Health/Lippincott Wiliams Wilkins. 1 September 2007. p. 963.  
  38. ^ The American Psychiatric Publishing Textbook of Psychopharmacology (Schatzberg, American Psychiatric Publishing Textbook of Psychopharmacology). USA: American Psychiatric Publishing, Inc. 31 July 2009. p. 471.  
  39. ^ Goswami, Meeta; R. Pandi-Perumal, S.; Thorpy, Michael J. (24 Mar 2010). Narcolepsy:: A Clinical Guide. Springer. p. 73.  
  40. ^ Kelsey, Jeffrey E.; Newport, D. Jeffrey; Nemeroff, Charles B. (2006). Principles of psychopharmacology for mental health professionals. Hoboken, N.J.: Wiley-Liss. p. 269.  
  41. ^ Lee-chiong, Teofilo (24 April 2008). Sleep Medicine: Essentials and Review. Oxford University Press, USA. pp. 463–465.  
  42. ^ Trevor, Anthony J.; Katzung, Bertram G.; Masters, Susan B. (1 January 2008). Katzung Trevor's pharmacology: examination board review. New York: McGraw Hill Medical. p. 191.  
  43. ^ Sjö O; Hvidberg EF; Naestoft J; Lund M (4 April 1975). "Pharmacokinetics and side-effects of clonazepam and its 7-amino-metabolite in man". Eur J Clin Pharmacol 8 (3–4): 249–54.  
  44. ^ Veall RM; Hogarth HC (22 November 1975). "Letter: Thrombocytopenia during treatment with clonazepam". Br Med J 4 (5994): 462.  
  45. ^ Alvarez N; Hartford E; Doubt C (April 1981). "Epileptic seizures induced by clonazepam". Clin Electroencephalogr 12 (2): 57–65.  
  46. ^ Ishizu T, Chikazawa S, Ikeda T, Suenaga E; Chikazawa; Ikeda; Suenaga (July 1988). "[Multiple types of seizure induced by clonazepam in an epileptic patient]". No to Hattatsu (in Japanese) 20 (4): 337–9.  
  47. ^ Bang F; Birket-Smith E; Mikkelsen B (September 1976). "Clonazepam in the treatment of epilepsy. A clinical long-term follow-up study". Epilepsia 17 (3): 321–4.  
  48. ^ a b Bruni J (7 April 1979). "Recent advances in drug therapy for epilepsy". Can Med Assoc J (PDF) 120 (7): 817–24.  
  49. ^ Rosenfeld WE, Beniak TE, Lippmann SM, Loewenson RB; Beniak; Lippmann; Loewenson (1987). "Adverse behavioral response to clonazepam as a function of Verbal IQ-Performance IQ discrepancy". Epilepsy Res. 1 (6): 347–56.  
  50. ^ White MC; Silverman JJ; Harbison JW (February 1982). "Psychosis associated with clonazepam therapy for blepharospasm". J Nerv Ment Dis 170 (2): 117–9.  
  51. ^ Williams A; Gillespie M (July 1979). "Clonazepam-induced incontinence". Ann Neurol 6 (1): 86.  
  52. ^ Sandyk R (August 13, 1983). "Urinary incontinence associated with clonazepam therapy". S Afr Med J 64 (7): 230.  
  53. ^ Anders RJ; Wang E; Radhakrishnan J; Sharifi R; Lee M (October 1985). "Overflow urinary incontinence due to carbamazepine". J Urol 134 (4): 758–9.  
  54. ^ Olsson R, Zettergren L; Zettergren (May 1988). "Anticonvulsant-induced liver damage". Am. J. Gastroenterol. 83 (5): 576–7.  
  55. ^ van der Bijl P, Roelofse JA; Roelofse (1991). "Disinhibitory reactions to benzodiazepines: a review". J. Oral Maxillofac. Surg. 49 (5): 519–23.  
  56. ^ Cohen LS, Rosenbaum JF; Rosenbaum (October 1987). "Clonazepam: new uses and potential problems". J Clin Psychiatry. 48 Suppl: 50–6.  
  57. ^ Lockard JS; Levy RH; Congdon WC; DuCharme LL; Salonen LD (December 1979). "Clonazepam in a focal-motor monkey model: efficacy, tolerance, toxicity, withdrawal, and management". Epilepsia 20 (6): 683–95.  
  58. ^ Vining EP (August 1986). "Use of barbiturates and benzodiazepines in treatment of epilepsy". Neurol Clin 4 (3): 617–32.  
  59. ^ Bernik MA; Gorenstein C; Vieira Filho AH (1998). "Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users". Journal of psychopharmacology (Oxford, England) 12 (2): 146–50.  
  60. ^ Adjeroud, S; Tonon, Mc; Leneveu, E; Lamacz, M; Danger, Jm; Gouteux, L; Cazin, L; Vaudry, H (May 1987). "The benzodiazepine agonist clonazepam potentiates the effects of gamma-aminobutyric acid on alpha-MSH release from neurointermediate lobes in vitro". Life Sciences 40 (19): 1881–7.  
  61. ^ Yokota, K; Tatebayashi, H; Matsuo, T; Shoge, T; Motomura, H; Matsuno, T; Fukuda, A; Tashiro, N (March 2002). "The effects of neuroleptics on the GABA-induced Cl− current in rat dorsal root ganglion neurons: differences between some neuroleptics" (PDF).  
  62. ^ Loiseau P (1983). "[Benzodiazepines in the treatment of epilepsy]". Encephale 9 (4 Suppl 2): 287B–292B.  
  63. ^ Scherkl R, Scheuler W, Frey HH; Scheuler; Frey (December 1985). "Anticonvulsant effect of clonazepam in the dog: development of tolerance and physical dependence". Arch Int Pharmacodyn Ther 278 (2): 249–60.  
  64. ^  
  65. ^ Bacia T; Purska-Rowińska E; Okuszko S (1980). "Clonazepam in the treatment of drug-resistant epilepsy: a clinical short- and long-term follow-up study". Monogr Neural Sci 5: 153–9.  
  66. ^ Browne TR (May 1976). "Clonazepam. A review of a new anticonvulsant drug". Arch Neurol 33 (5): 326–32.  
  67. ^ Sironi VA; Miserocchi G; De Riu PL (April 1984). "Clonazepam withdrawal syndrome". Acta Neurol (Napoli) 6 (2): 134–9.  
  68. ^ Sironi VA; Franzini A; Ravagnati L; Marossero F (August 1979). "Interictal acute psychoses in temporal lobe epilepsy during withdrawal of anticonvulsant therapy". J Neurol Neurosurg Psychiatry 42 (8): 724–30.  
  69. ^ Jaffe R; Gibson E (June 1986). "Clonazepam withdrawal psychosis". J Clin Psychopharmacol 6 (3): 193.  
  70. ^ Sechi GP; Zoroddu G; Rosati G (September 1984). "Failure of carbamazepine to prevent clonazepam withdrawal statusepilepticus". Ital J Neurol Sci 5 (3): 285–7.  
  71. ^ Welch TR; Rumack BH; Hammond K (1977). "Clonazepam overdose resulting in cyclic coma". Clin Toxicol 10 (4): 433–6.  
  72. ^ Honer WG; Rosenberg RG; Turey M; Fisher WA (November 1986). "Respiratory failure after clonazepam and amobarbital". Am J Psychiatry 143 (11): 1495.  
  73. ^ "Clonazepam, Prescription Marketed Drugs,". 
  74. ^ Jeffrey K Aronson (18 November 2011). Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. Elsevier. p. 73.  
  75. ^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 335-337.
  76. ^ a b Authier, N.; Balayssac, D.; Sautereau, M.; Zangarelli, A.; Courty, P.; Somogyi, AA.; Vennat, B.; Llorca, PM.; Eschalier, A. (November 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Ann Pharm Fr 67 (6): 408–13.  
  77. ^ Wolkove, N.; Elkholy, O.; Baltzan, M.; Palayew, M. (May 2007). "Sleep and aging: 2. Management of sleep disorders in older people". CMAJ 176 (10): 1449–54.  
  78. ^ Trimble MR; Cull C (1988). "Children of school age: the influence of antiepileptic drugs on behavior and intellect". Epilepsia. 29 Suppl 3: S15–9.  
  79. ^ Hollister LE (1975). "Dose-ranging studies of clonazepam in man". Psychopharmacol Commun 1 (1): 89–92.  
  80. ^ Bonkowsky HL; Sinclair PR; Emery S; Sinclair JF (June 1980). "Seizure management in acute hepatic porphyria: risks of valproate and clonazepam". Neurology 30 (6): 588–92.  
  81. ^ Reynolds NC Jr; Miska RM (April 1981). "Safety of anticonvulsants in hepatic porphyrias". Neurology 31 (4): 480–4.  
  82. ^ Karson CN; Weinberger DR; Bigelow L; Wyatt RJ (December 1982). "Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial". Am J Psychiatry 139 (12): 1627–8.  
  83. ^ a b Lander CM; Eadie MJ; Tyrer JH (1975). "Interactions between anticonvulsants". Proc Aust Assoc Neurol 12: 111–6.  
  84. ^ Pippenger CE (1987). "Clinically significant carbamazepine drug interactions: an overview". Epilepsia 28 (Suppl 3): S71–6.  
  85. ^ Saavedra IN; Aguilera LI; Faure E; Galdames DG (August 1985). "Phenytoin/clonazepam interaction". Ther Drug Monit 7 (4): 481–4.  
  86. ^ a b Windorfer A Jr; Sauer W (1977). "Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepin and dipropylacetate". Neuropadiatrie 8 (1): 29–41.  
  87. ^ Windorfer A; Weinmann HM; Stünkel S (March 1977). "[Laboratory controls in long-term treatment with anticonvulsive drugs (author's transl)]". Monatsschr Kinderheilkd 125 (3): 122–8.  
  88. ^ Khoo KC; Mendels J; Rothbart M; Garland WA; Colburn WA; Min BH; Lucek R; Carbone JJ; Boxenbaum HG; Kaplan SA (September 1980). "Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam". Clin Pharmacol Ther 28 (3): 368–75.  
  89. ^ Bendarzewska-Nawrocka B; Pietruszewska E; Stepień L; Bidziński J; Bacia T (January–Feb 1980). "[Relationship between blood serum luminal and diphenylhydantoin level and the results of treatment and other clinical data in drug-resistant epilepsy]". Neurol Neurochir Pol 14 (1): 39–45.  
  90. ^ McElhatton PR (November–Dec 1994). "The effects of benzodiazepine use during pregnancy and lactation". Reprod Toxicol 8 (6): 461–75.  
  91. ^ Iqbal, MM.; Sobhan, T.; Ryals, T. (Jan 2002). "Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant". Psychiatr Serv 53 (1): 39–49.  
  92. ^ Skerritt JH; Johnston GA (May 6, 1983). "Enhancement of GABA binding by benzodiazepines and related anxiolytics". Eur J Pharmacol 89 (3–4): 193–8.  
  93. ^ Lehoullier PF, Ticku MK; Ticku (March 1987). "Benzodiazepine and beta-carboline modulation of GABA-stimulated 36Cl-influx in cultured spinal cord neurons". Eur. J. Pharmacol. 135 (2): 235–8.  
  94. ^ Varotto M; Roman G; Battistin L (30 April 1981). "[Pharmacological influences on the brain level and transport of GABA. I) Effect of various antipileptic drugs on brain levels of GABA]". Boll Soc Ital Biol Sper 57 (8): 904–8.  
  95. ^ Battistin L, Varotto M, Berlese G, Roman G; Varotto; Berlese; Roman (February 1984). "Effects of some anticonvulsant drugs on brain GABA level and GAD and GABA-T activities". Neurochem Res 9 (2): 225–31.  
  96. ^ Meldrum BS (1986). "Drugs acting on amino acid neurotransmitters". Adv Neurol 43: 687–706.  
  97. ^ Jenner P; Pratt JA; Marsden CD (1986). "Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT". Adv Neurol 43: 629–43.  
  98. ^ Gavish M; Fares F (November 1985). "Solubilization of peripheral benzodiazepine-binding sites from rat kidney" (PDF). J Neurosci 5 (11): 2889–93.  
  99. ^ "Benzodiazepine Equivalency Table" based on NRHA Drug Newsletter, April 1985 and Benzodiazepines: How they Work & How to Withdraw (The Ashton Manual), 2002.[2]
  100. ^ Chouinard G (2004). "Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound". J Clin Psychiatry. 65 Suppl 5: 7–12.  
  101. ^ Macdonald RL; McLean MJ (1986). "Anticonvulsant drugs: mechanisms of action". Adv Neurol 44: 713–36.  
  102. ^ Tardy M; Costa MF; Rolland B; Fages C; Gonnard P. (April 1981). "Benzodiazepine receptors on primary cultures of mouse astrocytes". J Neurochem 36 (4): 1587–9.  
  103. ^ Gallager DW; Mallorga P; Oertel W; Henneberry R; Tallman J (February 1981). "{3H}Diazepam binding in mammalian central nervous system: a pharmacological characterization". J Neurosci (PDF) 1 (2): 218–25.  
  104. ^ Petkov V; Georgiev VP; Getova D; Petkov VV (1982). "Effects of some benzodiazepines on the acetylcholine release in the anterior horn of the lateral cerebral ventricle of the cat". Acta Physiol Pharmacol Bulg 8 (3): 59–66.  
  105. ^ Grandison L (1982). "Suppression of prolactin secretion by benzodiazepines in vivo". Neuroendocrinology 34 (5): 369–73.  
  106. ^ Camoratto AM; Grandison L (18 April 1983). "Inhibition of cold-induced TSH release by benzodiazepines". Brain Res 265 (2): 339–43.  
  107. ^ Taft WC; DeLorenzo RJ (May 1984). "Micromolar-affinity benzodiazepine receptors regulate voltage-sensitive calcium channels in nerve terminal preparations" (PDF). Proc Natl Acad Sci USA (PDF) 81 (10): 3118–22.  
  108. ^ Dreifuss FE; Penry JK; Rose SW; Kupferberg HJ; Dyken P; Sato S (March 1975). "Serum clonazepam concentrations in children with absence seizures". Neurology 25 (3): 255–8.  
  109. ^ Robertson MD; Drummer OH (May 1995). "Postmortem drug metabolism by bacteria". J Forensic Sci 40 (3): 382–6.  
  110. ^ Dresser, G.K.; Spence, J.D.; Bailey, D.G. (2000). "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition". Clin. Pharmacokinet. 38 (1): 41–57.  
  111. ^ "Monograph - Clonazepam -- Pharmacokinetics".  
  112. ^ Parry GJ (1976). "An animal model for the study of drugs in the central nervous system". Proc Aust Assoc Neurol 13: 83–8.  
  113. ^ Gerna M; Morselli PL (January 21, 1976). "A simple and sensitive gas chromatographic method for the determination of clonazepam in human plasma". J Chromatogr 116 (2): 445–50.  
  114. ^ Tokola RA; Neuvonen PJ (1983). "Pharmacokinetics of antiepileptic drugs". Acta neurologica Scandinavica. Supplementum 97: 17–27.  
  115. ^ Greenblatt DJ, Miller LG, Shader RI; Miller; Shader (October 1987). "Clonazepam pharmacokinetics, brain uptake, and receptor interactions". J Clin Psychiatry. 48 Suppl: 4–11.  
  116. ^ Ebel S; Schütz H (February 27, 1977). "[Studies on the detection of clonazepam and its main metabolites considering in particular thin-layer chromatography discrimination of nitrazepam and its major metabolic products (author's transl)]". Arzneimittelforschung 27 (2): 325–37.  
  117. ^ Edelbroek PM; De Wolff FA (October 1978). "Improved micromethod for determination of underivatized clonazepam in serum by gas chromatography" (PDF). Clinical chemistry (PDF) 24 (10): 1774–7.  
  118. ^ "Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits".  

External links

  • Rx-List - Clonazepam
  • Poisons Information Monograph - Clonazepam
  • FDA prescription insert
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.